Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
T. Numata (Tokyo, Japan), H. Miyagawa (Tokyo, Japan), K. Okuda (Tokyo, Japan), H. Utsumi (Tokyo, Japan), M. Hashimoto (Tokyo, Japan), S. Minagawa (Tokyo, Japan), T. Ishikawa (Tokyo, Japan), H. Hara (Tokyo, Japan), J. Araya (Tokyo, Japan), K. Kuwano (Tokyo, Japan). Predictor of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study. 2220

Member's Comments

No comment yet.

Related content which might interest you: Response to benralizumab in severe eosinophilic asthma after intermediate-to-poor response to mepolizumab : a retrospective study. Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 Neomacrolides in the treatment of patients with severe asthma and/or bronchiectasis: A retrospective observational study Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010 Development of asthma in patients with eosinophilic bronchitis: prospective follow up study Source: Eur Respir J 2002; 20: Suppl. 38, 51s Year: 2002 Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis Source: Eur Respir J, 56 (4) 2000151; 10.1183/13993003.00151-2020 Year: 2020 A single-center observational study assessing response to mepolizumab in severe eosinophilic asthma Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Effectiveness of omalizumab in Canadian patients with allergic asthma: A retrospective study. Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 Mepolizumab is effective in severe eosinophilic asthmatics: an Austrian real-life study. Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Super-responder analysis and real-world one year effectiveness of benralizumab in severe eosinophilic asthma Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 A retrospective observational study to characterize severe eosinophilic asthma in Taiwan Source: International Congress 2018 – Asthma and allergy in adults and children and their biomarkers Year: 2018 Omalizumab in severe allergic asthma associated with COPD: a multicentric cohort study Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021 Late Breaking Abstract - International, prospective real-world study of mepolizumab in patients with severe asthma at one year: REALITI-A Source: Virtual Congress 2021 – Advances in asthma treatment Year: 2021 Experience with Mepolizumab in a cohort of patients with eosinophilic severe persistent asthma Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Identifying factors associated with severe asthma exacerbations: a retrospective study Source: Eur Respir J 2007; 30: Suppl. 51, 626s Year: 2007 Cross-sectional, observational study to estimate the prevalence of the eosinophilic phenotype for Brazilian patients with severe asthma: the BRAEOS study Source: Virtual Congress 2020 – Clinical characteristics and diagnostic tools for phenotyping asthma and COPD Year: 2020 Real-world effectiveness of omalizumab in allergic asthma patients with low or high blood eosinophils: A retrospective claims analysis study Source: International Congress 2018 – New developments in the treatment of asthma Year: 2018 Analysis of pre-hospital management in hospitalized patients with bronchial asthma (BA) exacerbation: 6-year observational study Source: Eur Respir J 2006; 28: Suppl. 50, 313s Year: 2006 Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 The APEX study: A retrospective review of responses of severe allergic asthma patients to omalizumab on continuous or non-continuous oral corticosteroids in UK clinical practice Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E Year: 2011 Impact of subcutaneous allergoid AIT on patients with allergic rhinitis and/or asthma: A retrospective real-life, long-term cohort analysis Source: Virtual Congress 2020 – Management of allergy, asthma and COPD Year: 2020 The ARIETTA study: baseline demographics in a real-world setting in patients with severe asthma Source: International Congress 2017 – Bronchial asthma management Year: 2017